Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
16 hedge funds and large institutions have $66.4M invested in Strongbridge Biopharma plc. in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.3M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$15.4M |
| 3 |
BC
Broadfin Capital
New York
|
+$11.9M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$7.03M |
| 5 |
TAF
Tredje AP-fonden
Se-111 91 Stockholm,
Sweden
|
+$6.54M |
Top Sellers
SBBP Hedge Fund Activity: Q4 2015 in Review
16 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2015, worth a combined $66.4M.
Buyers outnumbered sellers: 16 funds opened new SBBP positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $19.3M.
- 16 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $66.4M of Strongbridge Biopharma plc. stock for Q4 2015.
- 16 funds opened new Strongbridge Biopharma plc. positions in Q4 2015 and 0 closed out, a net change of +16 holders.
- The largest Strongbridge Biopharma plc. buyer in Q4 2015 was RA Capital Management, an estimated $19.3M added.
Based on aggregated 13F filings for Q4 2015.